ZBIOHealthcare · BiotechnologyZBIO Stock Forecast: Zenas BioPharma, Inc. Price Predictions for 2026-2027
The 8 Wall Street analysts covering Zenas BioPharma, Inc. hold a median 12-month price target of $45 — +42.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
ZBIO stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Zenas BioPharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (88): The shares have been drifting up relative to others.
Issuance (6): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Zenas BioPharma, Inc. — and when they’d sell — is the membership.
ZBIO stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ZBIO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +42.9% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $44 |
| 14 May 2026 | Morgan Stanley | Maintains | Equal-Weight | $21 → $22 |
| 17 Mar 2026 | Citigroup | Maintains | Buy | — |
| 17 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 17 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2026 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Feb 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Jan 2026 | Morgan Stanley | Downgrade | Equal-Weight | — |
| 22 Dec 2025 | Wedbush | Reiterates | Outperform | — |
| 26 Nov 2025 | Evercore ISI Group | Initiates | Outperform | — |
| 13 Nov 2025 | Morgan Stanley | Maintains | Overweight | — |
| 28 Oct 2025 | Citigroup | Maintains | Buy | — |
| 28 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 28 Oct 2025 | Morgan Stanley | Maintains | Overweight | — |
| 9 Oct 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 9 Oct 2025 | Wedbush | Maintains | Outperform | — |
| 16 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Mar 2025 | Wedbush | Initiates | Outperform | — |
| 12 Mar 2025 | Guggenheim | Reiterates | Buy | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
ZBIO analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Zenas BioPharma, Inc. (ZBIO) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.6×
- Price / sales
- 198.5×
- Price / book
- 5.2×
- EV / EBITDA
- −6.1×
Cheaper than 70% of US stocks
Cheaper than 3% of US stocks
Cheaper than 20% of US stocks
Cheaper than 80% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −100.0%
- Gross margin
- —
- Operating margin
- −3704.9%
- Net margin
- 0.0%
Higher than 1% of US stocks
Higher than 3% of US stocks
Higher than 30% of US stocks
- Return on equity
- −137.1%
- Return on assets
- −29.1%
- Dividend yield
- 0.0%
Higher than 10% of US stocks
Higher than 14% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
ZBIO vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ZBIO appears on the weeks it earns a place.
Frequently asked questions about ZBIO stock
What is the ZBIO stock price forecast for 2026-2027?
The 8 Wall Street analysts covering Zenas BioPharma, Inc. have a median 12-month price target of $45, with estimates ranging from $22 to $59. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ZBIO stock a buy right now?
Of the 8 analysts covering Zenas BioPharma, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Zenas BioPharma, Inc. 30 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ZBIO?
As at 1 Aug 2026, Zenas BioPharma, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (88 of 100).
Will ZBIO stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts implies +42.9% from the last close, and Ticker Nerd's factor model ranks Zenas BioPharma, Inc. 30 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ZBIO stock forecast for 2030?
No analyst covering Zenas BioPharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ZBIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $59 over the next 12 months.
How has ZBIO stock performed over the past year?
Zenas BioPharma, Inc. returned +102.0% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Zenas BioPharma, Inc. do?
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases.
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company focuses on advancing innovative immunology-based treatments, with a strong commitment to addressing diseases characterized by significant unmet medical needs. Zenas BioPharma's pipeline features lead candidates such as obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, and orelabrutinib, a highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in Phase 3 development for multiple sclerosis and other autoimmune indications. The firm's portfolio also includes other monoclonal antibodies and immunomodulators under investigation for disorders like immunoglobulin G4-related disease and systemic lupus erythematosus. Guided by values emphasizing innovation, urgency, and patient impact, Zenas BioPharma operates with the aim of bringing novel treatment options to patients, their families, and caregivers, ultimately seeking to improve quality of life and redefine therapeutic possibilities in the autoimmune sector.
CEO Mr. Leon Oliver Moulder Jr., M.B.A. · 167 employees · United States · https://zenasbio.com